English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduUsing previously taken diagnostic computed tomography (CT) scans in place of CT simulation scans to plan simple palliative radiation treatments can substantially reduce the time some people spend waiting for urgent treatment, improving the patient experience, a new study suggests.
Tag: Cancer Research
Accelerated radiation treatment could reduce head and neck cancer patient burden in low- and middle-income countries
A type of head and neck cancer predominantly diagnosed in people who reside in low- and middle-income countries may be treated effectively with fewer, but higher doses of radiation, a large new international study suggests.
Precision medicine navigators increase genomic testing rates for Black patients with prostate cancer
The presence of a clinical navigator to act as a liaison between people with prostate cancer and the health care system greatly increases the likelihood that patients, especially Black patients, will receive advanced testing that can help predict the severity of their disease and guide treatment, a new study suggests.
Short-course radiation as effective as standard treatment for patients who opt for breast reconstruction after mastectomy
In a first-of-its-kind study, people with breast cancer who underwent implant-based breast reconstruction immediately following a mastectomy reported that getting fewer, higher doses of radiation was just as effective as standard radiation, did not increase side effects and saved them time and money.
High-dose radiation offers new treatment option for older patients with inoperable kidney tumors
Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation, a new study from Australian and Dutch researchers suggests.
Sexual activity and vaginal dilation associated with fewer side effects after cervical cancer treatment
People who engage in sexual activity or vaginal dilation after chemoradiation treatment for cervical cancer are at lower risk for long-term side effects, according to a new study from researchers in Austria.
Liquid biopsies can rapidly detect residual disease following cervical chemoradiation, study finds
Two liquid biopsy tests that look for the presence of human papillomavirus (HPV) in the blood accurately identified patients with a high risk of cervical cancer recurrence after the completion of chemoradiation, a new study confirms.
High cure rate, low toxicity maintained with shortened radiation treatment for intermediate risk prostate cancer, study finds
People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggests.
Research Highlights for September 2023
Huntsman Cancer Institute shines the spotlight on new discoveries and cutting-edge cancer research. This month, researchers found that increasing access for Black people with prostate cancer may save lives. Also, the first patient in a new small cell lung cancer clinical trial has been enrolled, researchers are using an app to help adolescents and young adults manage cancer symptoms, and investigators are trying to reduce cognitive side-effects after chemotherapy.
MD Anderson Research Highlights: ASTRO 2023 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
When cancer takes a deadly turn: NUS study sheds a new light on cancer metastasis
The ability of cancer cells to metastasise, or spread from one part of the body to another, is one of the reasons why cancer can be extremely challenging to treat. However, the process that drives metastasis is complex and not fully understood.
Cancer Prevention and Research Institute of Texas awards $2 Million grant to SMU
The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded $2 million to recruit Annika Wylie to SMU and fund five years of her research, which focuses on the p53 gene, a naturally occurring tumor suppressor.
UChicago Medicine breaks ground on $815M project to build state’s first freestanding cancer care and research pavilion
The University of Chicago Medicine broke ground Tuesday on its $815 million project to build the state’s first and only standalone structure dedicated to cancer care and research. The 575,000-square-foot, seven-story pavilion builds off UChicago’s decades of work and leadership in cancer research and its prestigious National Center Institute designation as a Comprehensive Cancer Center.
Radiation oncology research and clinical trial results to be featured at ASTRO’s Annual Meeting in San Diego
The American Society for Radiation Oncology (ASTRO) announced today the 10 studies to be highlighted in the 2023 ASTRO Annual Meeting press program. Researchers will discuss their findings in news briefings held October 2 and 3 at the San Diego Convention Center and via live webcast.
Montefiore Einstein Comprehensive Cancer Center Awarded Comprehensive Designation from the National Cancer Institute
The newly renamed Montefiore Einstein Comprehensive Cancer Center (MECCC) has been awarded comprehensive designation by the National Cancer Institute (NCI) of the National Institutes of Health, the ultimate standard achieved by only 55 other NCI cancer centers in the U.S.
Mount Sinai Awarded $3.4 Million to Study Prostate Cancer in People With HIV
The National Cancer Institute has awarded the Icahn School of Medicine at Mount Sinai a $3.4 million grant to create a model that identifies the best prostate cancer treatment for people with HIV.
$1.92M NIH Award Fuels Research to Uncover How Key Protein Transport Mechanism Goes Awry in Cancer
The National Institute of General Medical Sciences has awarded Justin Taylor, M.D., a researcher at Sylvester Comprehensive Cancer Center, a five-year grant totaling $1.92 million for his work to better define the role of XPO1 (Exportin-1) in cancer.
Researchers awarded $2.5 million to develop brain cancer treatment
A multidisciplinary team of investigators from the UCLA Jonsson Comprehensive Cancer Center was awarded a $2.5 million Translational Team Science Award from the Department of Defense to develop a tailored treatment for glioblastoma, a deadly brain tumor with limited treatment options.
Gene therapy for brain tumor shows promising early results in humans
A new study from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer.
Gene therapy study identifies potential new treatment for liver cancer
Gene therapy with microRNA-22 produced better survival outcomes than the current FDA-approved drug for liver cancer and without noticeable toxicity in new mouse study.
Study Unlocks New Insight about Breast Cancer Risk
A new study led by a researcher at New York Institute of Technology provides insight that could change how scientists and clinicians understand genetic predisposition to breast cancer, a condition that affects one in eight U.S. women in her lifetime.
New LJI research has major implications for controlling T cell activity
According to new research in the journal Immunity, T cells have a nuclear receptor doing something very odd—but very important—to help them fight pathogens and destroy cancer cells.
Detecting risk of metastatic prostate cancer in Black men
To explore prostate cancer disparities, researchers looked to another disorder, diabetes. They conducted a clinical trial and report four biomarkers linked to a higher risk of metastatic prostate cancer in men of West African heritage. They will present their results at ACS Fall 2023.
July Research Highlights
Huntsman Cancer Institute investigators find a way to reduce infection after pancreatic surgery, discover the best treatment combination that’s cost effective for prostate cancer patients, and learn lung cancer patients receiving chemotherapy have more emergency department visits. They also found a genetic mutation that makes anemia more likely after chemotherapy, and a non-invasive way to remove brain tumors.
Penn State Health Children’s Hospital, Penn State College of Medicine bring international research consortium to Hershey to strengthen their fight against childhood cancer
Penn State Health and Penn State College of Medicine are strengthening their commitment to curing childhood cancer by bringing Dr. Giselle Saulnier Sholler, an internationally known physician-scientist, and her research consortium to Hershey.
Alternative cellular ‘fuels’ boost immunity
A metabolic by-product that is more prevalent during fasting may supercharge immune cells as they fight infection and disease, reports an early stage study by Van Andel Institute scientists and collaborators.
Jinghui Zhang, PhD, elected Fellow of the International Society for Computational Biology
Former Chair of Computational Biology honored with induction into Class of 2023 Fellows.
Cancer Research Institute Awards Over $28 Million in Grants to Fuel Immunotherapy Innovations
The Cancer Research Institute awarded $28.7 million in research grants and fellowships in the 2023 fiscal year ending June 30, 2023. In total, CRI distributed 73 awards that will advance cancer immunology research at 41 institutions in 10 countries. CRI grants were awarded to support projects involving a variety of immune-based approaches as well as the development of novel technologies that may help pave the way for the next generation of immunotherapies.
Discovery could lead to more treatments to prevent cancer and infectious diseases
Researchers have cracked how a particular type of immune cell develops in the body and protects against infection and disease. And the discovery could help in the development of more preventive treatments, according to a new study.
A step toward treating chemotherapy-resistant prostate cancer
Prostate cancer is resistant to one of the most powerful chemotherapy medications — cisplatin. Now, researchers in ACS Central Science have developed the first therapy of its kind that disrupts prostate cancer cells’ metabolism and releases cisplatin into the weakened cells, causing them to die.
Bowel Research UK chooses Symplectic Grant Tracker to power life-changing research
Bowel Research UK has chosen Symplectic Grant Tracker from Digital Science’s suite of flagship products to advance its aims of funding life-changing research into bowel cancer and other bowel diseases.
Breast cancer by age: Study reveals early mutations that predict patient outcomes
A study led by researchers at Sanford Burnham Prebys has found that in young women, certain genetic mutations are associated with treatment-resistant breast cancer.
Antibody Treatment Prevents Graft Versus Host Disease, a Major Bone Marrow Transplant Complication, in Advanced Preclinical Tests
An experimental antibody treatment largely prevented a bone marrow transplant complication called graft versus host disease (GVHD) in the intestines, without causing broad immune suppression, in a preclinical study led by researchers from Penn Medicine and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and published today in Science Translational Medicine.
KU Cancer Center receives historic $100 million gift from Sunderland Foundation to support new cancer research and care facility
The University of Kansas Cancer Center has received a $100 million lead gift to build a new, state-of-the-art destination cancer center. This gift is both the largest gift ever given by the Sunderland Foundation and the largest ever received by the University of Kansas and The University of Kansas Health System.
UCLA researchers uncover potential biomarkers of positive response to immunotherapy
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified potential new biomarkers that could indicate how someone diagnosed with metastatic melanoma will respond to immunotherapy treatment.
Markey Cancer Center study reveals persistent cancer disparities in Appalachian Kentucky
A recent University of Kentucky Markey Cancer Center study published in The Journal of Rural Health sheds light on Appalachian Kentucky’s alarming cancer burden, revealing striking disparities compared to non-Appalachian Kentucky and the rest of the country.Kentucky ranks first in the nation for cancer incidence and mortality rates, and Appalachian Kentucky bears the state’s greatest cancer burden, driven by disparities in health behaviors, such as smoking, and lower rates of cancer screening.
Treatment decisions in new era of individualized therapy for metastatic hormone-sensitive prostate cancer guided by Dana-Farber case study
This case study by Dana-Farber gives evidence-based guidance for how to navigate decision-making for individual patients with metastatic hormone-sensitive prostate cancer.
Fine-tuning 3D lab-grown mini tumors to help predict how patients respond to cancer therapies
Scientists from the UCLA Jonsson Comprehensive Cancer Center have developed a new method to bioprint miniature tumor organoids that are designed to mimic the function and architecture of real tumors. The improved process allows researchers to use an advanced imaging method to study and analyze individual organoids in great detail, which can help researchers identify personalized treatments for people with rare or hard-to-treat cancers.
ASCO: HER2-targeted antibody drug conjugate shows strong anti-tumor activity and durable responses across multiple tumor types
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types. These data from an interim analysis of the Phase II DESTINY-PanTumor02 study, led by The University of Texas MD Anderson Cancer Center, were presented today at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
New drug delays progression of glioma, a deadly brain cancer
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.
American Cancer Society Experts Presenting Key Research at 2023 ASCO Meeting
Scientists from the American Cancer Society are presenting research studies at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) June 2-6 in Chicago, Illinois.
ASCO: Targeted therapy for early breast cancer, progress treating recurrent glioma, PSMA PET scan advances and more
Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest research and clinical trial results on combination therapies for breast cancer, a potential new treatment for patients with recurrent glioma, and advances in PSMA PET guided radiotherapy for patients with prostate cancer, among other topics, at the American Society of Clinical Oncology’s annual meeting.
Renowned Researcher Bradley R. Cairns, PHD, Elected as a Fellow of the Royal Society
Cairns joins renowned scientists as part of the Royal Society, known for its significant role in many scientific discoveries. Cairns is the second current faculty member elected at the U.
American Society for Radiation Oncology (ASTRO) to host Annual Meeting in San Diego, October 1-4
Registration opens today for the American Society for Radiation Oncology’s (ASTRO) 65th Annual Meeting, which will be held at the San Diego Convention Center, October 1-4, 2023. Media registration is available at www.astro.org/astro2023press, and general registration is available at www.astro.org/annualmeeting.
New Computational Tool Identifies Novel Targets for Cancer Immunotherapy
Researchers at Children’s Hospital of Philadelphia (CHOP) and the University of California, Los Angeles (UCLA) have developed a computational platform capable of discovering tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets. The tool, called “Isoform peptides from RNA splicing for Immunotherapy target Screening” (IRIS), was described in a paper published today in the Proceedings of the National Academy of Sciences.
Computational biology superstar Sanju Sinha joins Sanford Burnham Prebys
Sanju Sinha, Ph.D., has joined Sanford Burnham Prebys as an assistant professor in the Cancer Molecular Therapeutics Program to continue his research on cancer development and drug discovery. He comes to Sanford Burnham Prebys from the Cancer Data Science Lab at the National Cancer Institute (NCI), where he trained to leverage the power of artificial intelligence to discover new drugs to prevent cancer.
You’ve got some nerve
Researchers at the University of Michigan Rogel Cancer Center and the School of Dentistry identified a new metric to articulate the relationship between nerve density and oral cancer.
Saturated fatty acids promote immune escape of oral cancers
A team from the University of Michigan Rogel Cancer Center and School of Dentistry, led by Yu Leo Lei, D.D.S., Ph.D., have identified a mechanism in mice for how obesity affects some oral cancers’ ability to escape from the immune system.
Targeting uncontrolled inflammation may hold the key to treating therapy-resistant cancers
Van Andel Institute scientists have pinpointed how a specific gene mutation triggers an inflammatory cascade that may drive development of treatment-resistant cancers.
Markey Cancer Center study identifies new treatment target for metastatic cancer
A new University of Kentucky Markey Cancer Center study reveals more about changes that happen to cancer cells when they metastasize and identifies a promising target for the treatment of metastatic breast cancer.Metastasis is when cancer cells spread from the primary tumor to surrounding tissues and distant organs in the body and is the primary cause for breast cancer mortality.